Rotigotine Transdermal Patch

Sanford, Mark; Scott, Lesley J.
August 2011
CNS Drugs;2011, Vol. 25 Issue 8, p699
Academic Journal
A transdermal patch formulation of the non-ergolinic dopamine agonist rotigotine (Neupro®) is indicated as monotherapy for the treatment of early Parkinson's disease and as combination therapy with levodopa throughout the course of the disease. Daily application of the rotigotine transdermal patch (referred to here as rotigotine) provided predictable release and absorption of rotigotine, with steadystate rotigotine concentrations reached within 1-2 days. In six large, well designed clinical trials, rotigotine was an efficacious treatment for Parkinson's disease. In early Parkinson's disease, rotigotine initiated without levodopa produced significantly greater improvements than placebo in the Unified Parkinson's Disease Rating Scale (UPDRS) summed motor and activities of daily living (ADL) scores, as well as significantly higher response rates. In a comparison with oral ropinirole, rotigotine did not meet a prespecified response-rate noninferiority criterion, although this may reflect the dosages used, which may not have been directly comparable. In advanced Parkinson's disease, rotigotine in combination with levodopa reduced 'off' time and improved motor functioning and ADL significantly more than levodopa plus placebo. Rotigotine was noninferior to oral pramipexole in reducing 'off' time, although it did not meet a response-rate noninferiority criterion. A recent trial focused on both motor and non-motor endpoints in patients with inadequate early morning motor control despite antiparkinsonian treatment (most received levodopa). Rotigotine improved morning motor functioning and reduced sleep disturbances, night-time motor symptoms, depressive symptoms, pain and functioning, and quality of life to a significantly greater extent than placebo. Rotigotine was generally well tolerated across the trials and in longer-term extension studies, with the most common treatmentemergent adverse events being application-site reactions, gastrointestinal disturbances, somnolence and headache. Application-site reactions were generally mild to moderate in severity; where reported, up to 3% of patients had severe skin reactions. Thus, rotigotine offers a novel approach to the treatment of Parkinson's disease and, given its ease of administration, efficacy in reducing disabling motor and non-motor symptoms, and acceptable tolerability profile, it has the potential to be an attractive treatment option for this highly debilitating disease.


Related Articles

  • Is Earlier Treatment of Parkinson's Disease Better? Henchcliffe, Claire // Neurology Alert;Feb2009, Vol. 27 Issue 6, p45 

    RASAGILINE IS AN IRREVERSIBLE MONOAMINE OXIDASE type B inhibitor indicated for symptomatic treatment of Parkinson's disease (PD), but laboratory data in cells and animal models has provided hope that it may also be neuroprotective. This study seeks to address its long-term use and possible...

  • Parkinson's. Portyansky, Elena // Drug Topics;5/3/99, Vol. 143 Issue 9, p39 

    Focuses on treatment options for the degenerative neurologic disorder known as Parkinson's disease. Neuroprotective therapy; Treatment guidelines; Pharmacist counseling for patients; Advantages of dopamine agonists over levodopa therapy.

  • Study supports first-line use of ropinirole for early PD.  // Formulary;Sep99, Vol. 34 Issue 9, p733 

    Reports on the findings that provide evidence for treating early-stage Parkinson's disease (PD) with a dopamine agonist and initiating levodopa only after PD symptoms. Comparison of a dopamine agonist with levodopa; Association with less risk of dyskinesias; Ropinirole as a first-line option...

  • Clinical Pharmacology of Dopamine Agonists in Parkinson's Disease. Lange, K.W. // Drugs & Aging;1998, Vol. 13 Issue 5, p381 

    Oral levodopa is the most effective symptomatic treatment for Parkinson's disease. Dopamine agonists are useful adjuvants to levodopa in the pharmacotherapy of parkinsonian patients. Monotherapy with dopamine agonists in early Parkinson's disease has been advocated in order to delay the...

  • What is the best initial treatment of Parkinson's disease? Schreck, Jennifer; Kelsberg, Gary; Rich, Joanne // Journal of Family Practice;Nov2003, Vol. 52 Issue 11, p897 

    There are no studies clearly demonstrating the best initial treatment for Parkinson's disease in the United States. A systematic review of randomized control trials recommends that drug choices should be based on each patient's individual symptoms and response to medication. In 2002, the...

  • Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment. Thanvi, Bhomraj; Lo, Nelson; Robinson, Tom // Postgraduate Medical Journal;Jun2007, Vol. 83 Issue 980, p384 

    Levodopa is the most effective drug for treating Parkinson's disease. However, long-term use of levodopa is often complicated by significantly disabling fluctuations and dyskinesias negating its beneficial effects. Younger age of Parkinson's disease onset, disease severity, and high levodopa...

  • UCB receives FDA approval for Parkinson's and restless legs syndrome treatment.  // PharmaWatch: CNS;May2012, Vol. 11 Issue 5, p5 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of UCB's Neupro which is a rotigotine transdermal system for treating Parkinson's disease (PD) and restless legs syndrome (RLS) in 2012. It indicates that Neupro is capable of stimulating dopamine receptors within...

  • Rotigotine Transdermal Patch: A Review of its Use in the Management of Parkinson's Disease. Baldwin, Claudine M.; Keating, Gillian M. // CNS Drugs;2007, Vol. 21 Issue 12, p1039 

    A transdermal patch formulation of the non-ergolinic dopamine agonist rotigotine (Neupro) is indicated for use as monotherapy in the treatment of early-stage Parkinson’s disease or, in the EU, as an adjunct to levodopa across all disease stages. Transdermal rotigotine is an...

  • Improved control of brittle Parkinsonism by separate administration of levodopa and benserazide. McLean, D.L.; Dean, B.C. // British Medical Journal (Clinical Research Edition);4/3/1982, Vol. 284 Issue 6321, p1001 

    Examines the efficacy of the separate administration of levodopa and benserazide for the control of brittle Parkinsonism. Deterioration of the control through the state of severe Parkinsonism to a state of incapacitating chorea; Method for re-establishing the control; Effect of food intake to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics